Completely Positive Maps and Classical Correlations

We expand the set of initial states of a system and its environment that are known to guarantee completely positive reduced dynamics for the system when the combined state evolves unitarily. We characterize the correlations in the initial state in terms of its quantum discord [H. Ollivier and W. H. Zurek, Phys. Rev. Lett. 88, 017901 (2001)]. We prove that initial states that have only classical correlations lead to completely positive reduced dynamics. The induced maps can be not completely positive when quantum correlations including, but not limited to, entanglement are present. We outline the implications of our results to quantum process tomography experiments.Comment: 4 pages, 1 figur

Operational approach to open dynamics and quantifying initial correlations

A central aim of physics is to describe the dynamics of physical systems. Schrodinger's equation does this for isolated quantum systems. Describing the time evolution of a quantum system that interacts with its environment, in its most general form, has proved to be difficult because the dynamics is dependent on the state of the environment and the correlations with it. For discrete processes, such as quantum gates or chemical reactions, quantum process tomography provides the complete description of the dynamics, provided that the initial states of the system and the environment are independent of each other. However, many physical systems are correlated with the environment at the beginning of the experiment. Here, we give a prescription of quantum process tomography that yields the complete description of the dynamics of the system even when the initial correlations are present. Surprisingly, our method also gives quantitative expressions for the initial correlation.Comment: Completely re-written for clarity of presentation. 15 pages and 2 figure

Comparing the effect of STan (cardiotocographic electronic fetal monitoring (CTG) plus analysis of the ST segment of the fetal electrocardiogram) with CTG alone on emergency caesarean section rates: study protocol for the STan Australian Randomised controlled Trial (START).

BACKGROUND: Cardiotocography is almost ubiquitous in its use in intrapartum care. Although it has been demonstrated that there is some benefit from continuous intrapartum fetal monitoring using cardiotocography, there is also an increased risk of caesarean section which is accompanied by short-term and long-term risks to the mother and child. There is considerable potential to reduce unnecessary operative delivery with up to a 60% false positive diagnosis of fetal distress using cardiotocography alone. ST analysis of the fetal electrocardiogram is a promising adjunct to cardiotocography alone, and permits detection of metabolic acidosis of the fetus, potentially reducing false positive diagnosis of fetal distress. METHODS: This study will be a single-centre, parallel-group, randomised controlled trial, conducted over 3 years. The primary hypothesis will be that the proportion of women with an emergency caesarean section on ST analysis will not equal that for women on cardiotocography monitoring alone. Participants will be recruited at the Women's and Children's Hospital, a high-risk specialty facility with approximately 5000 deliveries per annum. A total of 1818 women will be randomised to the treatment or conventional arm with an allocation ratio of 1:1, stratified by parity. The primary outcome is emergency caesarean section (yes/no). Statistical analysis will follow standard methods for randomised trials and will be performed on an intention-to-treat basis. Secondary maternal and neonatal outcomes will also be analysed. Additional study outcomes include psychosocial outcomes, patient preferences and cost-effectiveness. DISCUSSION: Approximately 20% of Australian babies are delivered by emergency caesarean section. This will be the first Australian trial to examine ST analysis of the fetal electrocardiogram as an adjunct to cardiotocography as a potential method for reducing this proportion. The trial will be among the first to comprehensively examine ST analysis, taking into account the impact on psychosocial well-being as well as cost-effectiveness. This research will provide Australian evidence for clinical practice and guideline development as well as for policy-makers and consumers to make informed, evidence-based choices about care in labour. TRIAL REGISTRATION: ANZCTR, ACTRN1261800006268 . Registered on 19 January 2018

Effect of dietary lipid source on expression of lipid metabolism genes and tissue lipid profile in juvenile spiny lobster Sagmariasus verreauxi

The spiny lobster Sagmariasus verreauxi is an emerging lobster species for intensive aquaculture. The lack of any nutritional information required for feed development in this species initiated this study to understand the effect of different dietary lipid sources on tissue lipid profiles and expression of selected lipid metabolising genes. Krill oil, marine oil (blend of fish oils), and vegetable oil (combination of linseed and palm oil), were utilised to formulate three experimental feeds with different phospholipid, triacylglycerol and polyunsaturated fatty acid profiles. Experimental feeds were administered to freshly moulted juvenile S. verreauxi for 50 to 55 days, to determine the effect of lipid sources on the nutritional status, fatty acid composition and expression of genes related to fatty acid biosynthesis, β-oxidation, lipid catabolism and regulation of lipid metabolism. While there were no significant differences in terms of weight gain and mortality among different dietary treatments, the fatty acids composition in the hepatopancreas and to some extent, muscle tissues correlated with the fatty acids composition of the respective dietary treatments. Vegetable oil diet resulted in higher expression of genes related to β-oxidation, which indicates selectivity towards utilisation of monounsaturated fatty acids for energy in this species. In tandem, genes related to fatty acid and cholesterol biosynthesis were upregulated, suggesting their importance in the marine lobster diet. This is the first report on the use of formulated feeds to successfully maintain juvenile S. verreauxi

Neurorehabilitation From a Distance: Can Intelligent Technology Support Decentralized Access to Quality Therapy?

Current neurorehabilitation models primarily rely on extended hospital stays and regular therapy sessions requiring close physical interactions between rehabilitation professionals and patients. The current COVID-19 pandemic has challenged this model, as strict physical distancing rules and a shift in the allocation of hospital resources resulted in many neurological patients not receiving essential therapy. Accordingly, a recent survey revealed that the majority of European healthcare professionals involved in stroke care are concerned that this lack of care will have a noticeable negative impact on functional outcomes. COVID-19 highlights an urgent need to rethink conventional neurorehabilitation and develop alternative approaches to provide high-quality therapy while minimizing hospital stays and visits. Technology-based solutions, such as, robotics bear high potential to enable such a paradigm shift. While robot-assisted therapy is already established in clinics, the future challenge is to enable physically assisted therapy and assessments in a minimally supervized and decentralized manner, ideally at the patient’s home. Key enablers are new rehabilitation devices that are portable, scalable and equipped with clinical intelligence, remote monitoring and coaching capabilities. In this perspective article, we discuss clinical and technological requirements for the development and deployment of minimally supervized, robot-assisted neurorehabilitation technologies in patient’s homes. We elaborate on key principles to ensure feasibility and acceptance, and on how artificial intelligence can be leveraged for embedding clinical knowledge for safe use and personalized therapy adaptation. Such new models are likely to impact neurorehabilitation beyond COVID-19, by providing broad access to sustained, high-quality and high-dose therapy maximizing long-term functional outcomes.ISSN:2296-914